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Male breast malignancy is extremely rare, and the
incidence is approximately 1% of all breast cancers [1].
Because of the rarity of the disease, contemporary natural
history, diagnostic approach, treatment regimen, and
prognosis about male breast cancer are not fully
understood compared with its female counterpart [2].
Consequently, the lack of awareness among both surgeons
and patients about male breast cancer often leads to
delayed diagnosis [1]. Despite a histology that is similar
to the female counterpart, male infiltrating ductal
carcinomas seem to have different immunohistochemical
characteristics [3]. Because early diagnosis can achieve
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better prognosis, early awareness of the disease is
important. In this study, all male breast cancer patients
treated surgically from 2000 to December 2005 were
retrospectively reviewed from the archives of the
Department of Pathology, Kaohsiung Municipal Hsiao-
Kang Hospital. Only one male primary breast cancer
(Case 1) was found. The incidence was approximately
0.7% of all breast cancers. Three male breast cancer cases
were retrieved from the archives of the Department of
Pathology, Kaohsiung Medical University Chung-Ho
Memorial Hospital between 1988 and January 2005. Two
patients were lost to follow-up. Only one clinical file was
available (Case 2). The incidence was also 0.7%, similar to
that of Kaohsiung Municipal Hsiao-Kang Hospital. Here
we present two rare cases from the Kaohsiung Municipal
Hsiao-Kang Hospital and Kaohsiung Medical University
Chung-Ho Memorial Hospital (the Table compares
various characteristics of these two patients). We hope
that better understanding of this malignancy will be
achieved after more reports are published.
© 2006 Elsevier. All rights reserved.
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CASE PRESENTATIONS
Case 1
A 70-year-old male patient presented with a history of
painless enlargement of a mass in the left breast near the
nipple. His family history was unremarkable. He had regular
follow-up for control of hypertension. He drank alcohol
occasionally and was a nonsmoker. The remaining past
medical history was unremarkable. Physical examination
showed a hard, firm, fixed, and palpable lump without
nipple inversion and discharge in his left breast. The size
was 1.2 cm in its greatest diameter. No axillary or
supraclavicular lymphadenopathy was found. An
ultrasonogram of the left breast demonstrated a 1.2-cm
nodule in the inner region near the nipple with indeterminate
sonographic diagnosis. The shape was irregular, and the
margin was jagged. No retrotumoral acoustic effect was
noted. The nodule revealed hypoechoic layering and
heterogeneity. The specimen submitted for frozen section
consisted of one tissue fragment measuring 2 = 2.2 = 2 cm.
On serial section, a grayish white and ill-circumscribed
tumor measuring 1.1 = 0.9 = 1.2 cm was revealed. The
intraoperative diagnosis was malignancy. The patient
underwent modified radical mastectomy and axillary
lymph node dissections. Specimen samples later sent to
pathology consisted of the breast and axillary content.
An elliptical piece of skin that was included measured
7.9 = 1.4 cm. A 1.2-cm surgical section line was found from
the margin of the areola. The nipple and areola were
unremarkable. There was no evidence of edema or
inflammation in the skin. Microscopic examination showed
grade II infiltrating ductal carcinoma with a minor
component of carcinoma in situ. All of the margins were
free of disease (Figure 1). A metastatic lesion was noted in
1 of 11 lymph nodes that were dissected, measuring 1.9 cm
in its greatest diameter. The lesion was estrogen-receptor
(75%) and progesterone-receptor (80%) positive.
Immunohistochemical tests for HER-2/neu, p53, and
Ki-67 were all negative. The tumor revealed a partial
positive result for E-cadherin (~75%) and Bcl-2 (90%)
(Figure 2). Partial loss of expression was also found in the
staining of cytokeratin 7. The patient had chemotherapy
and returned regularly to the clinic for follow-up. He was
still disease-free nearly 4 months after surgery.
Case 2
A 76-year-old male presented with a 2-year history of painless
enlargement of a lump in the right nipple and areola. His
family history was unremarkable. He had regular follow-up
for control of hypertension and diabetes mellitus. He had
had one episode of cerebrovascular accident 7 years earlier,
but without any complications. The remaining medical history
Figure 1. Microscopic appearance of tumor tissue (Case 1). Cords of
hyperchromatic cancer cells with occasionally focal luminal formation
(H&E, original magnification = 400). Left lower smaller insert: infiltrating
ductal carcinoma of no special type with cords and sheets of carcinoma
cells (H&E, original magnification = 200). Right lower smaller insert:
sheets of closely packed carcinoma cells invade adjacent adipose tissue
(H&E, original magnification = 40).
Table. Comparison between two male patients with breast
cancer
Parameter Patient 1 Patient 2
Age of diagnosis 70 years old 76 years old
Site Left Right
Tumor size 1.1 cm 2 cm
(greatest diameter) (greatest diameter)
Histologic grade II II
Estrogen receptor + (75%) + (20%)
Progesterone receptor + (80%) + (100%)
HER-2/neu – –
Ki-67 – –
p53 – + (60%)
E-cadherin + (75%) + (80%)
Bcl-2 + (90%) + (70%)
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was unremarkable. Physical examination showed a hard,
firm, fixed, and palpable lump without nipple inversion and
discharge in his right breast. The size was approximately
2 cm in its greatest diameter. No axillary or supraclavicular
lymphadenopathy was found. The ultrasonogram of the
right breast demonstrated a 2-cm nodule in the nipple and
areola. The impression was malignancy. The shape was
irregular and the margin was jagged. No retrotumoral acoustic
effect was noted. The nodule revealed a hypoechoic region.
The specimen submitted for frozen section consisted of one
tissue fragment measuring 2.1 = 1.4 = 0.2 cm. On serial
section, there was a grayish white and ill-circumscribed
tumor measuring 2.1 cm in its greatest diameter. The
intraoperative diagnosis was malignancy. The patient
underwent modified radical mastectomy and axillary lymph
node dissections. Specimen samples later sent to pathology
consisted of the breast and axillary content. An elliptical
Figure 2. Immunohistochemical features of tumor tissue (Case 1). (A) Totally negative Ki-67; (B) negative p53 (C); positive E-cadherin with
partial loss of expression in the smaller insert. (D) Positive Bcl-2 with partial loss of expression in the smaller insert (all original magnification
= 200).
piece of skin that was included measured 16.3 = 4.5 cm. A
3.5-cm surgical section line was found from the margin of
the areola. A residual tumor measured 3.5 = 2.7 = 3.5 cm in
size. The nipple and areola were unremarkable. There was
no evidence of edema or inflammation in the skin.
Microscopic examination showed grade II infiltrating ductal
carcinoma with direct invasion in overlying skin, areola,
and nipple. All of the margins were free of the disease
(Figure 3). A metastatic lesion was noted in one of the two
sentinel lymph nodes dissected out, measuring 0.5 cm in its
greatest diameter. The lesion was positive for estrogen
receptor (20%) and progesterone receptor (100%).
Immunohistochemical testing was negative for HER-2/neu
and Ki-67. The tumor tested partially positive for E-cadherin
(~80%), p53 (60%), and Bcl-2 (70%) (Figure 4). The patient
did not have chemotherapy. He was regularly followed up
in our clinic and was disease-free nearly 3 years after surgery.
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DISCUSSION
Benign or malignant male breast disease is relatively rare,
being diagnosed in only 0.5–1 in 100,000 men per year [4].
The etiology and pathogenesis are not fully understood, it
accounts for less than 1% of all breast malignancies, and is
responsible for only 0.1% of male cancer deaths [4–6].
The most common symptom and sign of male breast
cancer is a painless, asymmetric, or centrally located mass
with a slight predilection for the left side of the breast [5].
The mass may range from 0.5 to 12.5 cm [5]. The diagnostic
features of male breast cancer are similar to its female
counterpart, such as bloody discharge in 75% of patients,
changes in the areola in as many as 20% of cases, and Paget’s
disease in 5% of patients [5].
The average age at diagnosis is around 60 years. The
disease is rare in young men and occurs in men 10 years
older than equivalent female patients [5]. Several
Figure 4. Immunohistochemical features of tumor tissue (Case 2). (A) No Ki-67 expression. (B) Strong nuclear staining for p53 with partial loss
of expression in the smaller insert. (C) Positive E-cadherin with partial loss of expression in the smaller insert. (D) Positive Bcl-2 with partial loss
of expression in the smaller insert (all original magnification = 200).
Figure 3. Microscopic appearance of tumor tissue (Case 2). Organoid
hyperchromatic cancer cells with distinct nucleoli (H&E, original
magnification = 400). Left lower smaller insert: there is a prominent
cribriform pattern (H&E, original magnification = 200). Right lower
smaller insert: carcinoma of no special type with organoid arrangement
(H&E, original magnification = 40).
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predisposing factors have been extensively discussed [6].
Among these, family history is thought to be a major risk
factor [4]. Predisposing breast cancer genes have been
searched for, and BRCA1 and BRCA2 are the most notable
[4]. BRCA2 plays an important role in male breast
malignancies, whereas the definite role of BRCA1 in
pathogenesis of male breast cancer remains to be elucidated
[4,6]. Males with the BRCA2 mutation are reported to be
younger and associated with a poorer prognosis than
female patients [7]. Other factors have been proposed,
including excess exogenous estrogen, androgen deficiency,
imbalanced estrogen–testosterone, hormonal changes due
to hypogonadism, mumps orchitis, undescended testes,
testicular injury, hepatic disease, Klinefelter’s syndrome,
obesity, benign breast disease, gynecomastia, a history of
breast malignancies, and environmental factors, such
as radiation or certain occupations [5,6]. Despite the
extensiveness of this investigated list, discordance still
exists; for example, it is unclear whether gynecomastia is
truly a risk factor [7], and although alcohol use, liver
disease, electromagnetic field radiation, and diet have
been proposed as possible etiologies, findings are
inconsistent across studies [5–7]. In our cases, no obvious
risk factor was found.
Infiltrating ductal carcinoma composes about 70% of
male breast cancers, the majority of which are of high
histologic grade [5]. Lobular carcinoma was once thought
to be nonexistent because male breasts lack lobules and
acini, but a few case reports have been found [5]. Different
characteristics, prognosis, and sensitivity to hormonal
treatment seem to exist between male and female breast
cancers [3].
Higher percentages of estrogen and progesterone
receptor reactivity are associated with male breast cancers
and may be a result of low estrogen levels [3,5,7]. The higher
percentage of reactivity probably explains the good
hormonal response in men [5]. HER-2/neu proto-oncogene
overexpression is seen in 20–30% of female breast cancers,
whereas, in contrast, only 5% positivity is seen in male breast
malignancies [7,8]. The HER-2/neu is a transmembrane
receptor protein with tyrosine kinase activity and is
associated with poor outcome in female breast cancers [8].
HER-2/neu overexpression seems not to correlate with
pathologic grade, tumor state, hormonal status, and lymph
node status in male breast malignancies [9]. HER-2/neu
gene amplification does not correlate completely with
overexpression [8]. Despite the lack of standardized
immunostaining protocol and standardized interpretive
positive criteria, immunohistochemistry remains the most
commonly used method to assess the HER-2/neu status [3,
8]. Our cases showed positive estrogen and progesterone
receptors and negative HER-2/neu. The role of HER-2/neu
in male breast cancers has still to be elucidated, but probably
does not play an important role in predicting clinical
behavior [5,8,9].
First discovered in 1979, p53 was thought to be the first
tumor suppressor gene that can repress abnormal cell activity
[10]. Its overexpression is found in a majority of tumors but
occurs at a significantly lower frequency in female breast
cancers [3,5,10]. Some studies have found that p53 was low
in male carcinomas and high in female malignancies [3].
Others have found a similar incidence in both sexes [11]. In
female breast cancers, p53 has been proved to be significant
in prognosis and is associated with recurrence, more
aggressive disease, and a poorer survival rate [5,10,11].
Other studies, however, have found no such correlation
[11]. The proliferation marker, Ki-67, is found in 38% of
male patients. Decreased survival was significantly
associated with positive results for Ki-67 [11]. Case 1 had
neither p53 nor Ki-67 activity. Case 2 had 60% of p53
expression with 0% of Ki-67.
Male breast cancers also differ from female malignancies
in their high expression of Bcl-2 in 94% of cases [3,11].
Notably, the Bcl-2 family genes are associated with apoptosis,
as markers of cells resistant to apoptosis [11,12]. Bcl-2
proteins are involved in the mitochondrial apoptosis
pathway, and their overexpression is observed in many
tumors, including solid tumors as well as hematologic
malignancies [13]. Some investigators have found inverse
immunostaining between p53 and Bcl-2 in both male and
female malignancies [3]. Bcl-2 proteins inhibit apoptosis,
and, consequently, we would not expect an inverse
relationship between these two [3,12]. No explanation was
found for this intriguing phenomenon—either in male
breast cancers or in female counterparts [3]. The role of
Bcl-2 proteins in cancer pathogenesis is confusing. Some
studies have suggested that their expression might be a
predictor of response to endocrine therapy and favorable
prognosis [12], whereas others have proposed that their
overexpression might confer resistance to chemotherapy
[13]. In our patients, Bcl-2 was positive in 90% (Case 1) and
70% (Case 2) of tumor cells. In our literature search, we
failed to find studies concerned with the meaning of
heterogeneous loss of Bcl-2 expression.
E-cadherin is a transmembrane glycoprotein and a
calcium-dependent cell–cell adhesion protein [14,15]. It is
expressed on the cytoplasmic membrane and plays a role in
epithelial tumorigenesis [16]. The gene is located on
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chromosome 16q22.1 [15]. Because of its potential role as an
invasion/tumor suppressor and unproved role in
predisposition to breast cancer, it has been widely studied
[15,16]. Normal mammary ductal epithelial cells strongly
express E-cadherin [14]. Some studies have proposed that
only lobular tumors showed E-cadherin mutation [17].
E-cadherin is frequently found in infiltrating ductal
carcinomas and is responsible for complete loss of
immunoreactivity in invasive lobular carcinomas [14,15].
Its expression is also a good diagnostic aid in differential
diagnosis between invasive ductal and lobular carcinomas
[15]. Heterogeneous loss of expression is seldom described
in the literature and probably correlates with loss of
differentiation, acquisition of invasiveness, increased tumor
grade, metastatic behavior, and poor prognoses [15]. The
association between E-cadherin, estrogen and progesterone
receptors, and HER-2/neu is controversial, as is its role in
breast cancers [14–16]. Probably because of the rarity of
male breast cancers and lack of large numbers of patients,
studies of these potential markers are difficult. In our cases,
we also observed 25% (Case 1) and 20% (Case 2) loss of
E-cadherin expression.
Traditionally, mammography has an important role in
modality of investigation. High-frequency linear transducers
also play an increasingly important role in the field of
biopsy and imaging [18]. The ultrasonographic features of
male breast carcinomas are the same as those seen in
females, having hypoechoic and irregular margins [18].
Our patients showed imaging features similar to those in
the literature [18].
Although some studies are involved in the molecular
aspects of male breast cancers, because of the possibly
different characteristics, prognosis, and treatment between
male and female malignancies, discrepancies still exist
[3,14–16,19]. The most important prognostic factors are
axillary nodal status, tumor grade, tumor size, and lymphatic
or vascular involvement [20]. When nodal status and tumor
stage are compared, the outcome seems equal for both male
and female cases [21]. The standard treatment for male
breast cancer is similar to female malignancies, including
modified radical mastectomy combined with sentinel
node biopsy and axillary nodes dissection [22,23]. Adjuvant
therapy includes hormonal therapy (tamoxifen),
radiotherapy, chemotherapy, and orchiectomy [22–24].
Possibly as a result of the rare occurrence and unawareness
of male breast cancer, delayed diagnosis and advanced
stages of malignancies are frequently encountered [1,25].
Male breast cancer must be considered when a male patient
presents at the clinic with a lump in his breast [25].
REFERENCES
1. Kidmas AT, Ugwu BT, Manasseh AN, et al. Male breast
malignancy in Jos University Teaching Hospital. West Afr J
Med 2005;24:36–40.
2. Schuchardt U, Seegenschmiedt MH, Kirschner MJ, et al.
Adjuvant radiotherapy for breast carcinoma in men: a 20-year
clinical experience. Am J Clin Oncol 1996;19:330–6.
3. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison
of prognostic markers detected by immunohistochemistry in
male and female breast carcinomas. Eur J Cancer 1996;32A:
1686–92.
4. Daltrey IR, Eeles RA, Kissin MW. Bilateral prophylactic
mastectomy: not just a woman’s problem. Breast 1998;7:236–7.
5. Ravandi-Kashani F, Hayes TG. Male breast cancer: a review of
the literature. Eur J Cancer 1998;34:1341–7.
6. Schofield A, Muir E, de Silva D, et al. Male breast cancer: the
importance of recognizing family and the preliminary results
of linkage analysis to BRCA1 and BRCA2. Breast 1996:147–51.
7. Giordano SH. A review of the diagnosis and management of
male breast cancer. Oncologist 2005;10:471–9.
8. Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male
and female breast carcinoma. Am J Surg 2001;182:389–92.
9. Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene
amplification and protein expression in primary male breast
cancer. Breast Cancer Res Treat 2004;84:215–23.
10. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer.
Breast Cancer Res 2002;4:70–6.
11. Heinig J, Jackisch C, Rody A, et al. Clinical management of
breast cancer in males: a report of four cases. Eur J Obstet
Gynecol Reprod Biol 2002;102:67–73.
12. Zhang GJ, Kimijima I, Onda M, et al. Tamoxifen-induced
apoptosis in breast cancer cells relates to down-regulation of
bcl-2, but not bax and bcl-XL, without alternation of p53
protein levels. Clin Cancer Res 1999;5:2971–7.
13. Emi M, Kim R, Tanabe K, et al. Targeted therapy against
Bcl-2-related proteins in breast cancer cells. Breast Cancer Res
2005;7:R940–52.
14. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in
primary carcinomas of the breast and its distant metastases.
Breast Cancer Res 2003;5:R217–22.
15. Berx G, Van Roy F. The E-cadherin/catenin complex: an
important gatekeeper in breast cancer tumorigenesis and
malignant progression. Breast Cancer Res 2001;3:289–93.
16. Salahshor S, Haixin L, Huo H, et al. Low frequency of
E-cadherin alternations in familial breast cancer. Breast Cancer
Res 2001;3:199–207.
17. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at
chromosome 16 in breast carcinogenesis: different genetic
pathways in ductal and lobular breast cancer. Breast Cancer
Res 2002;4:5–8.
18. Stewart RA, Howlett DC, Hearn FJ. Pictorial review: the imaging
features of male breast disease. Clin Radiol 1997;52:739–44.
19. Ben Dhiab T, Bouzid T, Gamoudi A, et al. Male breast cancer:
about 123 cases collected at the Institute Salah-Azaiz of Tunis
from 1979 to 1999. Bull Cancer 2005;92:281–5. [In French]
20. Gateley CA. Male breast disease. The Breast 1998;7:121–7.
Immunohistochemical expression in male breast cancer
Kaohsiung J Med Sci May 2006 • Vol 22 • No 5 241
21. Deutsch M, Rosenstein MM. Ductal carcinoma in situ (DCIS)
of the male breast treated by lumpectomy and breast
irradiation. Clin Oncol (R Coll Radiol) 1998;10:204–5.
22. Bergs EA, Tanis PJ, Steller EP. Three men with breast cancer
Ned Tijdschr Geneeskd 2005;149:534–7. [In Dutch]
23. Volm MD. Male breast cancer. Curr Treat Options Oncol 2003;
4:159–64.
24. Zabel A, Milker-Zabel S, Zuna I, et al. External beam
radiotherapy in the treatment of male breast carcinoma:
patterns of failure in a single institute experience. Tumori 2005;
91:151–5.
25. Privitera A, Ellul E, Giordmaina R, et al. Male breast cancer:
report of 2 cases and review of the literature. Ann Ital Chir
2004;75:669–72.
242 Kaohsiung J Med Sci May 2006 • Vol 22 • No 5
